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Flow injection/sequential injection analysis (FIA/SIA) systems are suitable for carrying out automatic wet chemical/biochemical
reactions with reduced volume and time consumption. Various parts of the system such as pump, valve, and reactor may be
built or adapted from available materials. Therefore the systems can be at lower cost as compared to other instrumentation-based
analysis systems. Their applications for determination of biomarkers for liver diseases have been demonstrated in various formats
of operation but only a few and limited types of biomarkers have been used as model analytes. This paper summarizes these
applications for diﬀerent types of reactions as a guide for using ﬂow-based systems in more biomarker and/or multibiomarker
studies.
1.Introduction
Liverdiseases(hepaticdiseases)coverthebroadrangeofliver
disorders. The liver has many important functions including
breaking down toxic substances in the body and excreting
them into urine, producing and secreting bile to aid in
food digestion, converting glucose into stored glycogen and
vice versa, metabolizing ingested medicines to obtain active
ingredients, and producing blood-clotting factors, amino
acidsandcholesteroltotransportfat.Damagetotheliverwill
cause disruption of these functions which can cause serious
damage to the body. Even though the liver is considered the
only organ in the body that has exceptional capability in
replacing damaged cells, if too many liver cells are damaged,
the liver may fail to perform properly. Symptoms caused
from liver failure may not be obvious until many liver cells
(up to 75%) have malfunctioned [1]. Detection of liver
problems at an early stage would increase the chances of
curing them. Liver biopsy is currently the best method for
diagnosis of chronic liver diseases [2, 3]. However, biopsy
procedure involves the rather invasive method of taking a
smallpieceoflivertissuetobeexaminedunderamicroscope.
Therepetitionofliverbiopsyduringdiagnosisandtreatment
is hard on patients. Since liver diseases can also aﬀect almost
all other body systems, many substances/chemicals in the
body may respond to the malfunctioning of the liver. The
use of these substances/chemicals as biomarkers has become
an area of high interest in research as scientists look for
alternative noninvasive diagnostic approaches [2, 4, 5]. Even
though none of the biomarkers alone nor the liver biopsy
is perfect, they can be used for indication whether further
investigation is required [2].
Studies for the eﬀectiveness of biomarkers involve the
collection of numerous samples which may be available
at diﬀerent periods of time. Then the analyses of those
samples are usually carried out using the same method for
comparison.Mostofthepossiblebiomarkersbeingproposed
and under study are biomolecules such as proteins and
enzymes [6–9]. Analysis of biomarkers in samples with
complicated matrices like body ﬂuids requires highly speciﬁc
and sensitive techniques. Immunoassay is one of the most
widely used techniques for these purposes [10]. It can be
used to quantify proteins, enzymes, and other biomolecules
owing to the ﬂexibility of the immunoassay format and the
available antibodies. Fluorescence- and chemiluminescence-
based techniques are also of interest due to their high
sensitivity [11, 12]. However, these techniques are time
consuming and require a skillful operator. From the many2 International Journal of Hepatology
possible biomarkers proposed for liver diseases, only a few
are accepted for use and only one which is called fucosylated
Alpha-fetoprotein (AFP) is a United States Food and Drug
Administration approved biomarker [13, 14]. The study of
biomarkers for any disease seems to have the same common
problem of unreliable results. This is mainly due to having
insuﬃcient numbers of sample subjects and insuﬃcient
diverse population as well as the lack of reliable and easy
methods to manage various sets of samples and to validate
analytical methods [13, 15]. On the other hand, since each
research group around the world has access to diﬀerent
small sets of samples, it may be useful for the various
groups to conduct their studies using diﬀerent methods.
Even though the results cannot be compared directly, the
accumulated studies of those results/conclusions about the
same biomarker obtained from diﬀerent analysis methods
should help the medical community in drawing conclusions
about the trends and eﬀectiveness of a particular biomarker.
The eﬀectiveness of the biomarkers should be revealed with
similar signiﬁcance, no matter which methods were used to
quantify them.
Analysis technology has evolved into more rapid and low
volume operations. The automatic features of the analysis
system that can handle tedious and time-consuming analysis
protocols are in demand. This paper is focused on the ﬂow-
based analysis techniques called ﬂow injection/sequential
injection analysis (FIA/SIA) for use as alternative systems
for automatic and rapid quantiﬁcation of biomarkers for
liver diseases. The relatively low cost of these semi to
fully automatic systems may help broaden opportunities
for medical care/clinical studies in remote areas where
medical personnel are limited and also provide additional
information/results about the eﬀectiveness of the candidate
biomarkers.
2.Flow Injection/SequentialInjectionAnalysis
Flowinjectionanalysistechniquehasbeenemployedtoauto-
mate a wide variety of chemical/biochemical analyses since
itsinventionintheearly1970s[16].Owingtoitsfeasibilityin
coupling with various types of detectors, the applications are
numerous.Sincepartsofthesystemscanbemadeinhouseor
replaced as suitable, the cost of the systems is relatively lower
thanmanyothercommercialinstrumentation-basedanalysis
systems. This makes ﬂow injection/sequential injection anal-
ysis systems especially suitable for low-budget laboratories.
A simple ﬂow injection system, see Figure 1, is composed of
a pump for drawing solutions (reagents) into the system via
pump tubing. An injection valve is used as an introduction
port for sample to merge into the stream of continuously
ﬂowing reagent. Detectable product is formed while ﬂowing
and simultaneously it enters the detector and then proceeds
out to waste. Various types of pump and valve may be used.
The most common types are peristaltic pump and a six-
port switching valve (similar to one used in HPLC system).
Unlike most commercial instrumentation-based analysis
systems, the FIA and SIA systems may be built/assembled
in house. The beneﬁcial feature of ﬂow injection systems is
the ﬂexibility of the formats and designs that can be created
based on applications. Various companies oﬀer parts (i.e.,
pumps, valve, detector, tubing, nuts, and ferrule) for various
purposes. These parts can be adapted for use in ﬂow-based
systemsdependingonbudgetandtheﬂowsystemdesign.For
example,intheearlyyearsofFIdevelopmentandapplication
inlow-budgetlaboratories,anIVbaghungatacertainheight
a n dac h e a pa q u a r i u mp u m pw e r er e p o r t e da ss u c c e s s f u l l y
used in place of a peristaltic pump [17]. Lower-cost solenoid
valves or plastic 3-way valves and tubing may also be used to
construct a hydrodynamic injection system instead of using
a more expensive commercial 6-port valve [18].
Reagent may be used as a carrier, where the sample is
injected into the reagent stream. However, if the reagent is
high cost and the sample is abundant, reverse FIA [19]m a y
be carried out by using the sample solution as the carrier
stream and introducing reagent at the injection point. The
product is formed while reagent and sample ﬂow together in
the small tubing after merging at the sample injection point.
The product zone, see Figure 2, has concentrated product
in the middle of the zone, and it is more diluted on both
sides of the zone due to dispersion of the solution plug in
the carrier stream. Therefore, when the product zone ﬂows
through the detector, the beginning of the zone (part A)
with low product concentration will enter ﬁrst, followed
by the high product concentration middle zone (part B)
and the end of zone with low product concentration (part
C). The resultant signal shows as peak signal, called FIA
gram, where the highest point resulted from the highest
productconcentrationinthemiddleofthezone.Detectionis
done much earlier before steady state; therefore the analysis
time is dramatically reduced as compared to conventional
batch-wise analyses where detection is normally done after
the reaction is completed or has reached steady state. The
constant ﬂowrate enables the detection of repetitive analyses
to be done at the same point of time. Thus, even though not
at steady state, the resultant FIA gram (peak height or peak
area) can be precisely related to the quantity of sample.
Later generations of ﬂow injection analysis technique
incorporate many pumps, valves, and tubing to accommo-
date more complicated chemical reactions that need many
reagents. The latest generation, called sequential injection
analysis [20], see Figure 3, has a downscaled system that
consumes even smaller volumes of reagents and samples in
af e wμL level with the use of a bidirectional syringe pump
and multiports selection valve. Reagents and sample can be
drawn sequentially and stacked into the mixing coil before
mixing while being pushed in reverse direction into the
detector. The operational steps from sample introduction,
chemical reaction, to detection are fully automated and pre-
cisely controlled with computer software. The system can be
programmed to stop for a desired period of time; therefore,
the study of slow reactions and those that require incubation
time such as immunoassay is possible. Accessories such as
lab-on-valve (LOV) unit with ports for attaching a ﬁber
optic spectrophotometric detector introduce more areas of
applications with real time detection [21–23].
Most research groups have reported that the ﬂow-based
systems not only increase sample throughput but also reduceInternational Journal of Hepatology 3
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Figure 2: Product zone in the ﬂow line.
the consumption of sample and reagents. This may be a
suitable approach for cases where body ﬂuid/blood samples
are limited or need to be divided for various other tests. As
compared to most conventional bench top wet chemistry,
ﬂowinjectionrequiresalotlesssamplevolume.Forexample,
intitration,samplevolumeinbatchmethodisinmLwhereas
in ﬂow-based titration, sample volume injected is in μL
[24]. A direct comparison between volumes used can only
be made when considering the same analyte and detection
methods.Somedownscaledbatchmethodsareabletoreduce
thevolumetoμL,butingeneral,FIusuallyrequiresrelatively
less sample volume for a particular analyte or sample being
studied. For example, the osmotic fragility test (OFT) of
red blood cells normally requires 20μL of undiluted blood
sample in batch spectrometric method whereas only 1μLo f
undiluted sample is required in the FI system where it is
tested in 100-fold dilution [25]. As compared to standard
bioassay technique such as ELISA, the volume required by
ﬂow-based systems is also usually lower. For example, the
assay of hyaluronan in serum using SI required 10μLo f
serum sample, as compared to the conventional routine
microplate assay that requires 120μL of serum sample [26].
For some commercially available ELISA kits such as the
cytokeratin 18 (CK18) biomarker kit which requires 50μL
of sample [27], no direct comparison of sample volume
usage can be made unless those samples have been tested4 International Journal of Hepatology
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within the ﬂow-based system, but lower sample volume
would be expected in the ﬂow-based system. Most lateral
ﬂowchromatographykitsmayrequireonlyadropofsample,
but they normally only yield a simple yes/no answer without
any detail of quantity.
3.Flow Injection/Sequential Injection Systems
as Alternative Tools for Rapid Determination
of Biomarkers for Liver Diseases
Table 1 summarizes the works that employed ﬂow injec-
tion/sequential injection systems and microﬂuidics devices
for rapid quantitative analysis of some substances that have
been reported as candidate biomarkers for liver diseases.
Most works emphasize the improved sample throughput.
Most works also demonstrated very high precision, reported
as percent relative standard deviation (%RSD), as shown in
Table 1. Various possible ways of operation and detection
using ﬂow-based systems are described.
3.1. Flow-Based Analysis System for Simple Reactions with
Various Types of Detectors. A ﬂow injection analysis system
can be used simply as an automatic system to carry out
the mixing of sample and reagent(s). The product formed
simultaneously ﬂows into the detector. Depending on the
reaction involved, product can be detected by coupling the
ﬂow injection system with suitable detectors (e.g., ﬂuores-
cence spectrometer [28–30], UV-Vis spectrometer [31, 32],
Rayleigh light scattering [33–35], or amperometer [36]).
Normally, the detection cells for the detectors are modiﬁed
to be compatible with the continuous ﬂow of solution in the
ﬂow systems by having inlet and outlet tubings, and they
arecommerciallyavailablewithvariousvolumesandformats
[37, 38]. Fluorescence is highly sensitive; therefore, it has
been employed as a detector for the analysis systems that
involve very low product volume such as in a nanoﬂuidic
system [30]. Sakai et al. demonstrated the formation of
micelle in the ﬂow line using nonionic surfactant Triton
X-100 (amphipathic molecules that arrange themselves in
spherical form in aqueous solution with hydrophilic ends
outwards and hydrophobic ends inward) [31] and also
the successive determination of multianalytes (e.g., human
serum albumin and glucose) from the same sample [39].
Even though the samples used in the report were from
diabetic subjects, it is clear that the same key idea of
multianalytesdetectioncanbeadaptedforliverdiseasescases
as well.
3.2. Flow-Based Analysis System for Multisteps Bioas-
say. A microcolumn packed with speciﬁc reagent-coated
microbeads can be used as a reactor to accommodate the
chemical/biochemical reaction. For example, Gao et al. [40]
utilized packed columns with enzyme-coated beads to carry
out multisteps enzymatic reactions. Another reported typeInternational Journal of Hepatology 5
Table 1: Summarization of works reported on liver diseases biomarkers using ﬂow-based analysis systems. FI: ﬂow injection; FI-BI: ﬂow
injection-bead injection; SI: sequential injection; LOC: lab on chip.
Flow-based
system Detector Reagent (s) Biomarker sample Detection
Limit
Working
range
Sample
throughput
%
RSD
Reference
no.
FI Florescence
spectrometer
Fluorescein, sodium
hypochlorite and
surfactant
A l b u m i ni nu r i n e 0 . 0 3μg/mL 0.05–
24μg/mL —0 . 8 [ 28]
FI Rayleigh light
scattering
Amide Black -10B Albumin in serum 0.11μg/mL — — <3[ 33]
D y ea c i dc h r o m eb l u eK Total protein in serum 85ng/mL 2–
40μg/mL 60/h <2[ 34]
Eriochrome black T 0.8μg/mL 7–
36μg/mL 90/h 0.76 [35]
FI Visible
spectrometer
Tetrabromophenolph-
thalein Et ester triton
x-100 (micelle
formation reagent)
A l b u m i ni nu r i n e 0 . 0 5m g / d L 0.15–
12mg/dL 30/h 1.2 [31]
Sulfate sulfatase
enzyme immobilized
on beads packed in
reactor
S u l f a t eb i l ea c i d — 1 – 7 5μM 15/h <1[ 40]
FI
Surface
Plasmon
resonance
spectrometer
Gold surface Albumin in serum 500μg/dL — 90s/sample — [46]
FI
Biolumines-
cence
spectrometer
coimmobilized
luciferase and
NADH:FMN
oxidoreductase on
hollow ﬁber reactor
3-alpha hydroxyl bile
acid in serum — 1–7.5μM >20/h 6–8 [41]
FI-BI Visible
spectrometer
Wheat germ
lectin-coated beads and
para-nitro phenyl
phosphate (PNPP)
Alkaline phosphatase in
serum 10U/L 10–
1000U/L 30min/sample 5-6 [32]
SI Visible
spectrometer
Hyaluronan standard
coated glass capillary,
biotinylated HA
binding proteins,
anti-biotin-HRP and
Tetra-methyl benzidine
substrate for
immunoassay
A l b u m i ni ns e r u m 9n g / m L Linear 25–
500ng/mL 20min/sample 3–5.5 [26]
Nanoﬂuidic
(LOC)
Fluorescence
spectrometer Fluorescein label Albumin in serum 0.3 pM 0.3–3 pM 200s/sample — [30]
Microﬂuidic Amperometer
Glass chip
Substrate conjugated
albumin packed in
microﬂow channel
Activity of enzymes
(glutamic oxaloace
tictransaminase,
glutamic pyruvic
transaminase,
γ-glutamyl
transpeptidase)
— Up to 100
−300U/L —— [ 36]
of reactor [41]i sac o m m e r c i a lh o l l o wﬁ b e rr e a c t o rw i t h
cuprammonium rayon membrane for immobilization of
enzyme. These works sought detection of bile acids in
urine and serum, respectively. Flow injection facilitated the
introduction of sample solution and reagent into the reactor
and simultaneously transported the colored/luminescent
product to the detector.
Many biomarkers are protein or enzyme which normally
can be determined using immunoassay technique. Conven-
tional immunoassay technique is carried out in microplate
format where multisteps incubations and washing are done
in an array of small plastic wells, each accommodating
100–500μL volume of solution. The test requires skillful
lab personnel to obtain precise and accurate results from6 International Journal of Hepatology
handling the microvolume solution and ensuring precise
incubation/washing time and volume for each well. The
immunoassay process usually takes 3–8 hours depending on
detailed steps. The good point of microplate immunoassay
format is that many samples can be analyzed in parallel.
However, in many circumstances, a small number of samples
may need to be analyzed with the demand of quick results.
In addition, in many areas of the world, skilled medical
personnel are not available to conduct such a complicated
test. More automated immunoassay systems where the
volume and time are controlled by using a constant ﬂow rate
pump to introduce and to draw solutions from the reaction
cell have been reported in various formats [42].
To change the format from conventional static immu-
noassay system to dynamic ﬂow formats, the reaction cell
has to be changed from being the wall of a microwell plate
to other forms of solid surfaces that can be accommodated
easily in the ﬂow of solution. Microbeads and capillary are
the main types reported. An example for the application
in biomarkers research is sequential injection-glass capillary
immunoassay [26, 43]. The sequential injection system was
used to precisely control the incubation time and small
volume of solution in the range of 10–80μLw h i c hi se v e n
smaller than some of those used in conventional microwell
plate format. A glass capillary was easily connected to the
system as part of the tubing that the solution conveniently
ﬂows through without any back pressure which may occur
when using beads. The wall of the glass capillary was used
as the solid surface for immobilization of biomolecules to be
employed in subsequent steps of competitive immunoassay.
Microbeads are used in immunoassay with the capability
to increase surface area to improve sensitivity. However,
beads that are packed or trapped in the reactor can cause
back pressure inside the ﬂow system, so a slow ﬂow rate
should be used. Example of sequential injection bead-based
immunoassay system was reported for determination of
hyaluronan, a possible biomarker for liver diseases [44]. The
lab-on-valve (LOV) unit with on-valve ﬁber optic spectrom-
eter can also be used in conjunction with functionalized
beads that are trapped in the LOV unit to obtain direct, real
time detection [45]. Although, there is no work reported
on its application for study of liver disease biomarkers, the
possibility exists for employing LOV bead immunoassay
for such a task. Nevertheless, employing beads in the ﬂow
system would require more sophisticated control systems
than most low-budget laboratories could devise unless pre-
existing equipment were to be adapted.
3.3. Flow-Based Analysis System with Preconcentration Capa-
bility. The use of microbeads in another aspect, other
than using them as a solid surface for immobilization of
biomolecules as used in immunoassay, is reported as a
preconcentration surface to accumulate analyte of interest
before detection. The ﬂow of solution within an easily
designed cell for trapping beads and releasing beads when
needed is called a ﬂow injection-bead injection system. An
example of such a system for alkaline phosphatase in human
serum was demonstrated [32]. Even though the work used
beads coated with wheat germ lectin for speciﬁc binding
for bone-alkaline phosphatase, it should be able to combine
with total alkaline phosphatase test to estimate for liver
alkaline phosphatase. The use of membrane for the same
purpose of improvement of sensitivity was also reported.
With-state-of-theartdevelopmentinnanotechnology,nano-
poremembraneusedwithelectrokineticﬂuidﬂowasanano-
ﬂuidic protein accumulator was claimed to oﬀer a much
higher sensitivity in the analysis of human serum albumin
than other methods [30].
By using a detection method that can measure the dif-
ferences of surface properties before and after binding to
the target analyte, such as surface plasmon resonance (SPR)
technique, the amount of bound analyte on the surface
could be quantitated directly without the need to add any
reagents. Aoki and Toyama [46] demonstrated this system
by determination of human serum albumin in urine using
gold as an adsorption surface. A ﬂow injection system was
employed for continuously feeding the sample containing
uric protein onto the gold surface.
4. Remarks
As can be observed from Table 1, most published works that
demonstrated ﬂow-based systems for liver diseases biomark-
ers used the same limited types of target analytes, that is,
serum albumin and total protein. There are many substances
in body ﬂuids that have been reported as potential biomark-
ers for liver diseases. Determination of these diﬀerent
biomarkers at the same time may provide better conclusion
about the existence of the diseases. Therefore, future studies
using ﬂow injection/sequential injection systems should
focus on various other possible biomarkers as well as
applicationsforconductingsimultaneousdetectionofmulti-
biomarkers from one shot of sample. Trends in development
of analytical devices have also been gearing toward a point
of care purpose. The main challenges are to develop the
systemforsolution introduction withcontrollableﬂowrates,
eﬀective reagent mixing, and detection unit in downscaled
format that can be integrated into compact stand-alone
devices.
5. Conclusion
Various formats of ﬂow injection/sequential injection anal-
ysis and micro-/nanoﬂuidic systems can be set up to study
biomarkers. Even though few works have reported on the
study of liver disease biomarkers using ﬂow-based systems,
works related to determination of protein and enzymes are
numerousandshouldbeadaptableforstudiesofliverdisease
biomarkers. These ﬂow-based systems are versatile and can
be used as an alternative method for rapid screening of
biomarkers to aid in disease diagnosis. Their low-volume
consumption is particularly suitable for the study of a
biomarker, in which samples may be divided for many other
tests,eithertoevaluatediﬀerentbiomarkersortoaccompany
the initial biomarker test.International Journal of Hepatology 7
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